Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

Milestone Pharmaceuticals

Milestone is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Our partnership

Milestone Pharma is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.

Contact

Dion Madsen, Founding partner at Amplitude Venture Capital.

Investment year: 2012
Industry sector: Drugs
Region: Quebec
Website

Recent news

2017-08-01

Milestone Pharmaceuticals Closes $55 Million Series C Financing

Learn More
2016-06-15

Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017

Learn More
2016-01-25

Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

Learn More
View All News

Certain news link to external sites and are presented in French only.